Post-Market CorPath Registry on the CorPath 200 System in Percutaneous Coronary Interventions
Status: | Recruiting |
---|---|
Conditions: | Angina, Peripheral Vascular Disease, Peripheral Vascular Disease, Peripheral Vascular Disease, Cardiology, Cardiology, Cardiology |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 12/17/2016 |
Start Date: | August 2013 |
End Date: | August 2017 |
Contact: | Chris Cain, RN |
Email: | chris.cain@corindus.com |
Phone: | (508) 653-3335 |
A Post-Market Registry for the Evaluation of the CorPath 200 System Effectiveness in Percutaneous Coronary Interventions
To collect data on the routine patterns of use, safety and effectiveness, including the
clinical and technical performance of the CorPath 200 System, in the delivery and
manipulation of coronary guidewires and stent/balloon catheters during PCI procedures.
clinical and technical performance of the CorPath 200 System, in the delivery and
manipulation of coronary guidewires and stent/balloon catheters during PCI procedures.
This is a prospective, single-arm, open-label, multi-center patient registry of the CorPath
200 System to examine its performance during PCI procedure and patient outcomes through 72
hours post-procedure or hospital discharge, whichever occurs first.
200 System to examine its performance during PCI procedure and patient outcomes through 72
hours post-procedure or hospital discharge, whichever occurs first.
Inclusion Criteria:
1. Age >18 years.
2. Patients with coronary artery disease undergoing Percutaneous Coronary Intervention
(PCI) with the CorPath 200 system.
3. The subject or the legal representative has been informed of the nature of the study,
agrees to its provisions and has provided written informed consent.
Exclusion Criteria:
1. Concurrent enrollment in another device or drug study protocol that specifically
excludes concurrent enrollment or that prevents collection of data required in this
registry (concurrent participation in another registry is not an automatic exclusion
criterion for this study).
2. Failure/inability/unwillingness to provide informed consent.
We found this trial at
16
sites
Concord, North Carolina
Principal Investigator: Paul Campbell, MD
Click here to add this to my saved trials
1414 Kuhl Avenue
Orlando, Florida 32806
Orlando, Florida 32806
Principal Investigator: Vijaykumar Kasi, MD
Phone: 321-841-3706
Click here to add this to my saved trials
Boston, Massachusetts 02135
Principal Investigator: Joseph P. Carrozza, MD
Click here to add this to my saved trials
Charlottesville, Virginia 22903
(434) 924-0311
Principal Investigator: Michael Ragosta, MD
Phone: 434-982-1058
University of Virginia The University of Virginia is distinctive among institutions of higher education. Founded...
Click here to add this to my saved trials
Cleveland, Ohio 44194
Principal Investigator: Hiram Bezerra, MD
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Grand Rapids, Michigan 49503
Principal Investigator: David Wohns, MD
Phone: 616-486-2031
Click here to add this to my saved trials
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Jeffrey Moses, MD
Click here to add this to my saved trials
1250 E. Marshall St.
Richmond, Virginia 23298
Richmond, Virginia 23298
(804) 828-9000
Principal Investigator: Luis Guzman, MD
Virginia Commonwealth University Medical Center The Virginia Commonwealth University Health System is an urban, comprehensive...
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Rajiv Gulati, MD
Phone: 507-255-9405
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Syracuse, New York 13203
Principal Investigator: Ronald Caputo, MD
Click here to add this to my saved trials
Washington, District of Columbia
Principal Investigator: Itsik Ben-Dor, MD
Click here to add this to my saved trials